Q4 EPS Estimate for Neurocrine Biosciences Lifted by Analyst

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Leerink Partnrs boosted their Q4 2024 earnings estimates for shares of Neurocrine Biosciences in a report released on Tuesday, October 15th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of $1.97 for the quarter, up from their prior estimate of $1.84. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.19 per share. Leerink Partnrs also issued estimates for Neurocrine Biosciences' FY2025 earnings at $7.65 EPS, FY2026 earnings at $9.80 EPS, FY2027 earnings at $12.00 EPS and FY2028 earnings at $13.95 EPS.

A number of other brokerages also recently commented on NBIX. Guggenheim boosted their price objective on shares of Neurocrine Biosciences from $170.00 to $180.00 and gave the company a "buy" rating in a research report on Friday, August 2nd. StockNews.com raised Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a research report on Sunday, August 4th. BMO Capital Markets reduced their price target on Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating for the company in a report on Thursday. Cantor Fitzgerald restated an "overweight" rating and issued a $155.00 price objective on shares of Neurocrine Biosciences in a report on Monday, September 16th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Neurocrine Biosciences in a research note on Thursday, August 29th. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, Neurocrine Biosciences currently has a consensus rating of "Moderate Buy" and an average target price of $163.91.

Neurocrine Biosciences Trading Up 0.1 %

NASDAQ:NBIX traded up $0.11 on Thursday, hitting $118.46. 727,879 shares of the company's stock traded hands, compared to its average volume of 852,299. The company has a market cap of $11.92 billion, a PE ratio of 32.69 and a beta of 0.36. Neurocrine Biosciences has a 1 year low of $103.63 and a 1 year high of $157.98. The firm has a 50-day moving average price of $127.16 and a 200-day moving average price of $135.09.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Thursday, August 1st. The company reported $0.63 EPS for the quarter, missing the consensus estimate of $1.15 by ($0.52). The business had revenue of $590.20 million during the quarter, compared to analyst estimates of $545.98 million. Neurocrine Biosciences had a return on equity of 14.86% and a net margin of 16.00%. The business's quarterly revenue was up 30.4% on a year-over-year basis. During the same period last year, the business earned $0.95 EPS.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds have recently added to or reduced their stakes in the stock. Mather Group LLC. acquired a new position in shares of Neurocrine Biosciences during the first quarter worth approximately $26,000. RFP Financial Group LLC raised its position in Neurocrine Biosciences by 346.5% in the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company's stock worth $26,000 after purchasing an additional 149 shares during the last quarter. Ashton Thomas Private Wealth LLC acquired a new position in Neurocrine Biosciences during the 2nd quarter worth $28,000. Innealta Capital LLC bought a new position in Neurocrine Biosciences in the 2nd quarter valued at $30,000. Finally, New Covenant Trust Company N.A. acquired a new stake in shares of Neurocrine Biosciences in the 1st quarter valued at $32,000. Institutional investors own 92.59% of the company's stock.

Insiders Place Their Bets

In other news, insider Julie Cooke sold 12,632 shares of the business's stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $153.26, for a total value of $1,935,980.32. Following the sale, the insider now owns 18,202 shares in the company, valued at approximately $2,789,638.52. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Neurocrine Biosciences news, Director Gary A. Lyons sold 11,570 shares of the business's stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $150.43, for a total value of $1,740,475.10. Following the transaction, the director now owns 119,047 shares of the company's stock, valued at approximately $17,908,240.21. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Julie Cooke sold 12,632 shares of the firm's stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $153.26, for a total value of $1,935,980.32. Following the completion of the sale, the insider now owns 18,202 shares of the company's stock, valued at approximately $2,789,638.52. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 59,968 shares of company stock worth $8,999,632 over the last quarter. Company insiders own 4.30% of the company's stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.